S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$81.44
$81.44
50-Day Range
N/A
52-Week Range
$26.41
$81.48
Volume
N/A
Average Volume
3.55 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MDVN stock logo

About (MDVN) Stock (NASDAQ:MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

MDVN Stock News Headlines

Notable ETF Outflow Detected - HYLB
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Medivation Alzheimer's Drug Fails Pivotal Study
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Core Medalist ETFs
The Connor Phillips Show
Medivation Stock Hits New 52-Week High (MDVN)
Medivation (MDVN) Stock Surges, Will Explore Sale
See More Headlines
Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2016
Today
4/18/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDVN
CUSIP
58501N10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

MDVN Stock Analysis - Frequently Asked Questions

How were (MDVN)'s earnings last quarter?

(MDVN) (NASDAQ:MDVN) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analyst estimates of $214.52 million. The business's quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the business earned $0.58 EPS.

What other stocks do shareholders of (MDVN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

This page (NASDAQ:MDVN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners